Kodiak Sciences (NASDAQ:KOD) Shares Gap Up Following Analyst Upgrade

Kodiak Sciences Inc. (NASDAQ:KOD)’s share price gapped up before the market opened on Friday after UBS Group raised their price target on the stock from $50.00 to $80.00. The stock had previously closed at $39.76, but opened at $41.89. UBS Group currently has a buy rating on the stock. Kodiak Sciences shares last traded at $44.9810, with a volume of 1,727,148 shares changing hands.

Several other research analysts have also issued reports on KOD. Weiss Ratings reiterated a “sell (e+)” rating on shares of Kodiak Sciences in a research note on Thursday, January 22nd. HC Wainwright restated a “buy” rating and issued a $58.00 price objective (up from $38.00) on shares of Kodiak Sciences in a report on Friday. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $35.43.

More Kodiak Sciences News

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Topline Phase 3 GLOW2 results showed Zenkuda’s superiority vs. sham on the trial’s primary endpoint (large DRSS improvements), supporting the program’s previously reported GLOW1 success and paving the way toward a regulatory filing. PR Newswire: GLOW2 Topline Results
• Positive Sentiment: Mainstream press and market outlets are reporting the trial win and the stock rally, driving increased investor attention and heavy trading. Widespread coverage increases the likelihood of more short‑term inflows. Reuters: Shares Surge After Late‑Stage Success
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and raised its price target to $58 (from $38), implying significant upside vs. recent levels — a bullish analyst signal that can attract additional institutional interest. Benzinga: HC Wainwright Price‑Target Raise
• Neutral Sentiment: Industry press notes Kodiak expects to move toward a BLA/filing next after the twin Phase 3 successes — a clear path to commercialization but still subject to regulatory review and timelines. This is constructive long term but timing and approval risk remain. BioWorld: BLA Filing Next
• Negative Sentiment: Options activity showed an unusual surge in put buying (3,472 puts, a ~1,256% jump vs. typical daily put volume), suggesting some traders are hedging or betting on pullbacks amid the sharp rally.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. EverSource Wealth Advisors LLC lifted its stake in shares of Kodiak Sciences by 1,221.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock worth $28,000 after buying an additional 916 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in Kodiak Sciences in the 4th quarter worth approximately $29,000. Headlands Technologies LLC lifted its position in Kodiak Sciences by 256.4% in the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock valued at $30,000 after acquiring an additional 5,815 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Kodiak Sciences in the 4th quarter valued at approximately $72,000. Finally, Strs Ohio purchased a new stake in Kodiak Sciences during the 4th quarter valued at $87,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Kodiak Sciences Trading Up 2.9%

The firm has a market capitalization of $2.17 billion, a PE ratio of -9.97 and a beta of 2.61. The firm has a 50 day simple moving average of $24.95 and a 200 day simple moving average of $21.62.

Kodiak Sciences Company Profile

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.